Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biotechnology company focused on the advancement of psychedelic therapeutics, recently announced the completion of its 74th pre-clinical study as part of its ongoing efforts to advance its proprietary psychedelic molecules into IND-enabling studies.
Cybin’s Research and Development team has undertaken 74 in-vitro and in-vivo examinations of the company’s growing portfolio of psychedelic chemicals with potential therapeutic applications for a variety of mental health disorders. To date, more than 50 new compounds have been examined for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding, and safety in collaborations with experienced contract research organizations in order to identify recommended candidates for further development.
The Company’s goal is to build a world-class portfolio of psychedelic compounds that can be developed into commercially viable medication candidates both internally and through future development partnerships.
Highlights from research and development:
- Completion of the 74th pre-clinical research and development study in support of moving CYB003 and CYB004 and other molecules closer to clinical development;
- Comparative data clearly shows multiple potential advantages over traditional psychedelic molecules, including faster onset of action, shorter duration of action, excellent oral bioavailability, significant brain penetration, and significantly less inter-subject variability. These properties are thought to translate to significantly better patient experiences;
- Safety and toxicology studies to FDA standards have begun in preparation for human clinical studies, which are expected to begin in early 2022; and
- Significant progress has been made in preparing CYB003 and CYB004 drug substances to FDA standards for human use in collaboration with an FDA approved manufacturer.
“Cybin continues to demonstrate superior properties of its CYB003 and CYB004 programs as we progress toward first-in-human studies, expected in early 2022. These experiments greatly expand our understanding of the potential therapeutic value of the studied compounds and further demonstrate Cybin’s strong research and development capabilities,” said Doug Drysdale, Cybin’s CEO.
